Dr. Mittendorf on Nelipepimut-S in Breast Cancer

Elizabeth A. Mittendorf, MD, PhD
Published: Tuesday, Apr 21, 2015



Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

Mittendorf has been involved with the development of nelipepimut-S, an immunodominant nonapeptide that will now be examined in the phase III PRESENT trial for patients with low to intermediate HER2 expression.

Nelipepimut-S was also tested in phase I/II studies and was found to be safe and effective, eliciting an immune response, Mittendorf explains. The vaccine was administered to patients with breast cancer who were found to be disease-free with standard of care therapy, with a purpose to prevent disease recurrence. Enrolled patients, who were at a 20% risk of disease recurrence, were at a 10% risk following treatment with nelipepimut-S.

A proposed trial will examine nelipepimut-S in the adjuvant setting for patients with DCIS. Patients will be vaccinated prior to surgery, and a blood test will determine if patients have an appropriate immune response, Mittendorf says.

<<< View more from the 2015 AACR Annual Meeting



Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

Mittendorf has been involved with the development of nelipepimut-S, an immunodominant nonapeptide that will now be examined in the phase III PRESENT trial for patients with low to intermediate HER2 expression.

Nelipepimut-S was also tested in phase I/II studies and was found to be safe and effective, eliciting an immune response, Mittendorf explains. The vaccine was administered to patients with breast cancer who were found to be disease-free with standard of care therapy, with a purpose to prevent disease recurrence. Enrolled patients, who were at a 20% risk of disease recurrence, were at a 10% risk following treatment with nelipepimut-S.

A proposed trial will examine nelipepimut-S in the adjuvant setting for patients with DCIS. Patients will be vaccinated prior to surgery, and a blood test will determine if patients have an appropriate immune response, Mittendorf says.

<<< View more from the 2015 AACR Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x